Yasuhiro Iwata

USPTO Granted Patents = 13 (Patent Applications = 1)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 4.7

ph-index = 8

Forward Citations = 112(Granted Patents)

Company Filing History:

6 out of 3,252

Nippondenso Co., Ltd.

Japan Aviation Electronics Industry, Limited

Years Active: 1981-2018

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9901571 - Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists (2018-02-27),

2. 9873695 - Serine derivatives as ghrelin receptor agonists (2018-01-23),

3. 9447066 - Salts and crystal forms (2016-09-20),

4. 9447065 - Pharmaceutical composition (2016-09-20),

5. 8697877 - Oxyindole derivatives with motilin receptor agonistic activity (2014-04-15),

6. 8653063 - N-substituted saturated heterocyclic sulfone compounds with CB2 receptor agonistic activity (2014-02-18),

7. 4408278 - Electric control method for automobile air conditioner (1983-10-04),

8. 4391320 - Method and an apparatus for air conditioning for vehicles by controlling (1983-07-05),

9. 4376879 - Button-less push switch boards (1983-03-15),

10. 4340113 - Electric control method and apparatus for automobile air conditioning (1982-07-20),

11. 4328855 - Method and apparatus for controlling automobile air conditioners (1982-05-11),

12. 4316251 - Electric control method for automobile air conditioner (1982-02-16),

13. 4259722 - Electric control method and apparatus for automobile air conditioner (1981-03-31),

Title: Yasuhiro Iwata: Innovator in Ghrelin Receptor Agonists

Introduction

Yasuhiro Iwata is a prominent inventor based in Aichi, Japan. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that act as ghrelin receptor agonists. With a total of 13 patents to his name, Iwata's work has the potential to impact therapeutic approaches for various disorders.

Latest Patents

Among his latest patents, Iwata has developed novel compounds such as Tetrahydropyrazolopyridine derivatives and Serine derivatives. The Tetrahydropyrazolopyridine derivatives are described as compounds that can modulate the growth hormone secretagogue receptor, also known as the ghrelin receptor. This invention includes processes for their preparation, pharmaceutical compositions, and their therapeutic uses. Similarly, the Serine derivatives also target the ghrelin receptor, offering potential treatment options for disorders mediated by this receptor.

Career Highlights

Iwata has worked with notable companies in the pharmaceutical industry, including Nippondenso Co., Ltd. and Raqualia Pharma Inc. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Throughout his career, Iwata has collaborated with esteemed colleagues such as Kiyoshi Usami and Masanori Naganoma. These partnerships have likely enhanced his research and development efforts in the field.

Conclusion

Yasuhiro Iwata's innovative work in the area of ghrelin receptor agonists showcases his dedication to advancing pharmaceutical science. His contributions through numerous patents reflect his commitment to improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.